Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 233

1.

Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?

Remington G.

Am J Psychiatry. 2006 Jul;163(7):1132-4. No abstract available.

PMID:
16816213
[PubMed - indexed for MEDLINE]
2.

Schizophrenia, antipsychotics and metabolic disease.

Reynolds GP.

J Psychopharmacol. 2007 Jun;21(4):355-6. No abstract available.

PMID:
17656424
[PubMed - indexed for MEDLINE]
3.

Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study.

Bai YM, Lin CC, Chen JY, Chen TT, Su TP, Chou P.

J Clin Psychiatry. 2011 Jun;72(6):751-6. doi: 10.4088/JCP.09m05402yel. Epub 2010 Nov 30.

PMID:
21208584
[PubMed - indexed for MEDLINE]
4.

Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.

Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH.

J Clin Psychiatry. 2004;65 Suppl 7:4-18; quiz 19-20. Review. No abstract available.

PMID:
15151456
[PubMed - indexed for MEDLINE]
5.

Metabolic syndrome with the atypical antipsychotics.

Pramyothin P, Khaodhiar L.

Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):460-6. doi: 10.1097/MED.0b013e32833de61c. Review.

PMID:
20717020
[PubMed - indexed for MEDLINE]
6.

Management of schizophrenia with obesity, metabolic, and endocrinological disorders.

Monteleone P, Martiadis V, Maj M.

Psychiatr Clin North Am. 2009 Dec;32(4):775-94. doi: 10.1016/j.psc.2009.08.003. Review.

PMID:
19944883
[PubMed - indexed for MEDLINE]
7.

Medication-induced weight gain and dyslipidemia in patients with schizophrenia.

Fenton WS, Chavez MR.

Am J Psychiatry. 2006 Oct;163(10):1697-704; quiz 1858-9. No abstract available.

PMID:
17012676
[PubMed - indexed for MEDLINE]
8.

Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.

Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA.

J Clin Psychopharmacol. 2008 Apr;28(2):132-7. doi: 10.1097/JCP.0b013e318166c4f7.

PMID:
18344722
[PubMed - indexed for MEDLINE]
9.

[Metabolic syndrome induced by antipsychotic drugs. The problem of obesity].

Jufe GS.

Vertex. 2008 Nov-Dec;19(82):338-47. Spanish.

PMID:
19424516
[PubMed - indexed for MEDLINE]
10.

Weight gain and antipsychotic medications.

Aquila R, Emanuel M.

J Clin Psychiatry. 1999 May;60(5):336-7. No abstract available.

PMID:
10362443
[PubMed - indexed for MEDLINE]
11.

[The appearance of metabolic syndrome in treatment with atypical antipsychotics].

Mosolov SN, Kabanov SO.

Zh Nevrol Psikhiatr Im S S Korsakova. 2003;103(11):62-9. Review. Russian. No abstract available.

PMID:
14681970
[PubMed - indexed for MEDLINE]
12.

Foreword. Importance of physical health in patients with schizophrenia.

Höschl C.

Eur Psychiatry. 2010 Jun;25 Suppl 2:S1-2. doi: 10.1016/S0924-9338(10)71698-9. No abstract available.

PMID:
20620880
[PubMed - indexed for MEDLINE]
13.

Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?

Housel AK, Waterbury N, Argo TR.

Issues Ment Health Nurs. 2009 Dec;30(12):803-5. doi: 10.3109/01612840903276712. Review. No abstract available.

PMID:
19916816
[PubMed - indexed for MEDLINE]
14.

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

Stahl SM, Mignon L, Meyer JM.

Acta Psychiatr Scand. 2009 Mar;119(3):171-9. doi: 10.1111/j.1600-0447.2008.01334.x. Review.

PMID:
19178394
[PubMed - indexed for MEDLINE]
15.

Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.

Webster D, Devarajan S, Gallant J, Harris A, Kopala LC.

Schizophr Res. 2002 Jul 1;56(1-2):187-9. No abstract available.

PMID:
12084432
[PubMed - indexed for MEDLINE]
16.

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.

Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones PB.

J Psychopharmacol. 2007 Jun;21(4):357-73. Review. Erratum in: J Psychopharmacol. 2008 Aug;22(6):699.

PMID:
17656425
[PubMed - indexed for MEDLINE]
17.

Association of initial antipsychotic response to clozapine and long-term weight gain.

Bai YM, Lin CC, Chen JY, Lin CY, Su TP, Chou P.

Am J Psychiatry. 2006 Jul;163(7):1276-9.

PMID:
16816235
[PubMed - indexed for MEDLINE]
18.

Metabolic syndrome in inpatients treated with clozapine.

Suzuki T.

J Clin Psychiatry. 2011 Jun;72(6):872-3; author reply 873-4. doi: 10.4088/JCP.11lr06864. No abstract available.

PMID:
21733485
[PubMed - indexed for MEDLINE]
19.

Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.

Newcomer JW.

J Clin Psychiatry. 2004;65 Suppl 18:36-46. Review.

PMID:
15600383
[PubMed - indexed for MEDLINE]
20.

Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.

Newcomer JW.

J Clin Psychiatry. 2007;68 Suppl 1:20-7. Review.

PMID:
17286524
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk